Ivosidenib (IVO; AG-120) in IDH1-mutant relapsed or refractory myelodysplastic syndrome: Updated results from a phase 1 study Meeting Abstract


Authors: DiNardo, C. D.; Foran, J. M.; Watts, J. M.; Stein, E. M.; de Botton, S.; Fathi, A. T.; Prince, G. T.; Stein, A. S.; Stone, R. M.; Patel, P. A.; Tallman, M. S.; Choe, S.; Wang, H.; Zhang, V.; Dai, D.; Fan, B.; Yen, K. E.; Kapsalis, S. K.; Hickman, D.; Agresta, S. V.; Liu, H.; Wu, B.; Attar, E. C.; Kantarjian, H. M.
Abstract Title: Ivosidenib (IVO; AG-120) in IDH1-mutant relapsed or refractory myelodysplastic syndrome: Updated results from a phase 1 study
Meeting Title: 7th Annual Meeting of the Society of Hematologic Oncology (SOHO 2019)
Keywords: clinical trial; targeted therapy; myelodysplastic syndromes; mds; mutation analysis; ivosidenib
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 19
Issue: Suppl. 1
Meeting Dates: 2019 Sep 11-14
Meeting Location: Houston, TX
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2019-09-01
Start Page: S340
Language: English
ACCESSION: WOS:000483480700373
DOI: 10.1016/j.clml.2019.07.341
PROVIDER: wos
Notes: Meeting Abstract: MDS-162 -- Source: Wos
Altmetric Score
MSK Authors
  1. Eytan Moshe Stein
    134 Stein
  2. Martin Stuart Tallman
    461 Tallman